Ensol Biosciences Company Description

Ensol Biosciences Inc., a biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases.

The company’s drug pipeline includes Peniel 2000, which is in Phase III clinical trial for the treatment of degenerative disc disease; Engedi 1000 that is in Phase II clinical trial for the treatment of osteoarthritis; and EAD100, a drug for animal osteoarthritis.

It also develops anticancer drugs, such as Charis 1000, which is in Phase I clinical trial for the treatment of triple negative breast cancer; Moriah 1000 that is in pre-clinical stage for the treatment of Alzheimer’s disease; Shiloah 1000, which is in pre-clinical stage for the treatment of type 1 diabetes; Allose 1000 that is in pre-clinical stage for the treatment of atopic dermatitis; EAD200, a drug for animal anti-cancer drug; and EAD300 for the treatment of porcine reproductive and respiratory syndrome.

In addition, the company offers contract drug development; chemistry, manufacturing, and controls contract drug development; and material synthesis and analysis services.

Further, it provides KISDD, a knowledge-based in silico drug discovery platform for the screening of new drug candidates for the treatment of a disease; and ETONS, an Ensol Trans-Omics network system.

The company was formerly known as Ensoltek Co., Ltd. and changed its name to Ensol Biosciences Inc. in August 2015.

Ensol Biosciences Inc. was founded in 2001 and is headquartered in Daejeon, South Korea.

Ensol Biosciences Inc.

Country	South Korea
Founded	2001
Industry	Biological Products, Except Diagnostic Substances
CEO	Hae-Jin Kim

Contact Details

Address: 51, Techno 10-ro Daejeon, 34036 South Korea
Phone	82 42 939 4500
Website	ensolbio.co.kr

Stock Details

Ticker Symbol	140610
Exchange	Korea New Exchange
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Hae-Jin Kim	Chief Executive Officer